1 / 60

Pediatric Asthma

Pediatric Asthma. Kimberly D. Watts MD, MS Pediatric Pulmonary Medicine. The Burden of Pediatric Asthma. The Scope of Asthma. Most common chronic disease of childhood Affects more than 7 million children in the United States Approximately 9% of all US children have asthma

nirav
Download Presentation

Pediatric Asthma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pediatric Asthma Kimberly D. Watts MD, MS Pediatric Pulmonary Medicine

  2. The Burden of Pediatric Asthma

  3. The Scope of Asthma • Most common chronic disease of childhood • Affects more than 7 million children in the United States • Approximately 9% of all US children have asthma • This rate has increased more than 160% in children under 5 in the last 20 years

  4. Healthcare Utilization

  5. The Cost of Asthma • The annual economic cost of asthma is $19.7 billion • Direct costs such as medications and indirect costs such as loss of productivity • 13 million school days are missed each year

  6. Rising Prevalence of Asthma • Increase in asthma prevalence from 1980 to 1996 of greater than 50 % • Largest increase in patients younger than 18 years old • Estimated current asthma prevalence in general increased between 2001-2009

  7. Why the increasing numbers? • Improved hygiene • Less exposure to pathogens disrupting innate immunity • Increased indoor air pollution • Caused by increase in energy efficient building • Increased incidence of early onset viral infections • Increase in host susceptibility • Small lungs due to prematurity or maternal smoking • Increased recognition and awareness

  8. Asthma death per 1,000 people with asthma ( 2007-09)

  9. Pathophysiology

  10. Definition of Asthma • Chronic inflammatory lung disease • Cough, wheezing, dyspnea and chest tightness • Airway narrowing that is partially or completely reversible • Increased airway responsiveness to stimuli

  11. Asthma Pathophysiology Overview Inflammation Narrowed airways Constricted muscles Airway hyper-reactivity Remodeled airway

  12. The wet dry asthma cough • Airways edema • Cellular infiltration • Eosinophils • Activated helper T cells • Mast cells • +/- neutrophils • Increased airway secretions • Secreted mucus • Desquamated lining cells • Intraluminal eosinophils

  13. Inflammation • Chronic inflammation occurs even in the most mild of symptomatic patients • Bronchoalveolar lavage of asthmatics demonstrates • Neutrophils, eosinophils, lymphocytes and mast cells • Cytokines including leukotrienes • Alterations in innate lung immunity • Impaired glutathione homeostasis • Decreased capacity to reduce reactive oxygen species

  14. Reversible Airflow Obstruction • Reduced expiratory airflow by spirometry • FEV1 < 80 % predicted and a reduced FEV1 / FVC ratio of < 0.80 • Significant reversibility is an increase of >12% in FEV1 from baseline

  15. Airway Hyperresponsiveness • Degree to which airways narrow in response to stimuli • Methylcholine • Cold Air • Histamine • Viral upper respiratory infections • Allergens • Air pollutants

  16. Normal vs. Asthma Airway

  17. Evaluation and Diagnosis

  18. Clinical Presentation • Most common cause of chronic cough in children older than 3 years old is asthma • Not always accompanied by wheezing • 80 % of children with asthma develop symptoms before 5 years of age • Breathlessness, chest tightness, chest pressure and chest pain • Poor school performance and fatigue

  19. Cough • Cough lasting more than 3 weeks • Night time cough • Cough to specific exposures • Dry and hacking cough • Productive with clear / white sputum • Usually eosinophils • With activity

  20. Wheezing • Polyphonic • Tends to be expiatory but can be inspiratory • Monophonic wheezes need further evaluation • Rings/slings • Malacia • When albuterol makes it worse

  21. Symptom Patterns • Intermittent exacerbations on a asymptomatic baseline • Chronic symptoms with worsening on exacerbations • Morning “ dipping” • Worsening of symptoms in the morning corresponding to the physiologic dip in pulmonary function • September epidemics • Viral infections, mycoplasma pneumoniae or Chlamydia pneumoniae infection

  22. Precipitating Factors and Risk Factors • Weather, second hand smoke, allergens and irritants • Wood fires, kerosene space heaters, room deodorizers • 30 % children with food allergy have asthma • Higher rate of intubation • Children of asthmatic parents odds ratio 2.6 ( 1 parents) and 5.2 ( 2 parents) • Sleep disordered breathing 3.6 fold increase risk for severe asthma • Higher BMI associated with greater asthma severity

  23. Diagnosis - Spirometry • National Asthma Educations and Prevention Program recommends spirometry to be performed in patients older than 5 years old • FEV1 < 80% predicted • FEF 25-75% less than 65% correlated with reversible airflow obstruction in children with normal FEV1 • Before and after bronchodilator • Increase in 12 % ( maybe 9% in children) • Normal spirometry or the lack of reversibility does not exclude the diagnosis of asthma

  24. Spirometry loops

  25. Diagnosis – Peak Flow • More variable and effort dependent • Wide variability in published predicted peak expiratory flow reference values • Can alter brand to brand • Peak flows should not be used to diagnose asthma • More helpful to monitor a patient’s response over time for a subgroup of patients

  26. Other Diagnostic Modalities • Impulse Oscillometry • Passive cooperation • Evaluates resistance pre and post bronchodilator • Bronchoprovocation Testing • Methylcholine, histamine , cold air , exercise • If patient fails empiric trial of asthma medsications • Chest x-ray • Congential malformations • Airspace disease • Signs of asthma

  27. Other Diagnostic Modalities • Sweat Chloride • Barium Swallow • TEF, reflux, vascular anomolies • Negative study cannot exclude GER • Allergy testing • Limited to seasons and suspect exposures • Exhaled nitric oxide • Levels elevated in patients with asthma • Chornic exposere to passive smoking may falsely decrease the levels

  28. Treatment

  29. Acute management

  30. Short Acting Beta Agonists • Relaxes smooth muscle • Overuse or regular use is associated with poor control • Theoretical concern regarding down regulation of beta receptors with chronic use • Can impact medication needed for urgent care

  31. Short acting medications • Albuterol • MDI with spacer or nebulizer • No role for oral albuterol given side effects • Levalbuterol • R- enantiomer – active isomer only • Approved MDI > 4 years old and neb > 6years old • Hospitalization rate lower among childrens who received levoalbuterol in the ER vs. albuterol but studies are mixed • Comparable, no evidence for superiority

  32. Ipratropium Bromide • Anti-cholinergic • Bronchodilator through smooth muscle relaxation • Adjuvant for albuterol in the ER • Reduce hospital admissions • Improve lung function in severe asthma • Also can use as an alternative agent to albuterol • Tracheomalacia • MDI not administered to soy or peanut allergy patients • Contains soy lecithin

  33. Steroids • 2007 NAEPP expert panel no longer recommends doubling dose of inhaled steroids for quick relief during acute exacerbations • Not found effective in reducing severity or progression of exacerbation • Higher dose ( > 2 times the normal dose) may be an alternative to oral steroids in mild exacerbations if patient does not tolerate oral steroids • Short course of oral steroids in addition to short acting beta agonists for acute exacerbations

  34. Chronic Management

  35. Who should get controller therapy? • 0 to 4 years old • Greater than 4 episodes of wheezing • Parental history of asthma • Patient with atopic dermatitis or allergies • Food allergies with eosinophilia or wheezing without colds • Require albuterol more than two days per week • Experiences severe illness < 6 weeks apart • 2 rounds of steroids in 6 months • Intermittent disease with severe exacerbation

  36. Controller therapy 5 years and older • For any persistent asthma • Any symptoms > 2 days a week • Night time symptoms greater than 2 times a month • Albuterol more than 2 days a week • Any interference with normal activity • Requires oral steroids more than once a year • Severity and interval of exacerbations

  37. Intermittent - - - > Step 1 Mild - - -> Step 2 Moderate - - -> Step 3 Severe - - -> Step 3 or 4

  38. Starting controller therapy • Two to six week interval is needed to assess response • Adherence with current regimen needs to be assessed before escalating therapy • Included assessment of barriers • When controlled for 2 to 6 months can begin reducing regimen

  39. Inhaled Corticosteroids • Inhibiting steps in the inflammatory cascade • Associated with reduction in • Symptoms • Irreversible decline in lung function • Asthma exacerbations • Functional limitations • Side effects from other medications • Reduction in parameters better than with leukotriene antagonist • First line control therapy for persistent ( or step 2 or greater ) asthma

  40. Inhaled Corticosteroids • Fraction of the dose than systemic steroids • Minimal side effects • Almost all the trivial amount of drug absorbed is deactivated after one pass through the liver • Differences in medications

  41. Inhaled Corticosteroids • Minimize risk of adverse side effects • Step down treatment to lowest possible dose to maintain control • Optimize adherence to lowest dose possible • Optimize delivery • Evaluate for complicating factors • Avoid triggers

  42. Inhaled Steroids and Disease Progression • Did not alter disease progression • Patients 2-3 years old with > 4 episodes of wheezing- - > fluticasone or placebo • Fluticasone fewer symptoms and exacerbations • At the last observational year no significant differences • Early , intermittent intervention had no effect on disease progression from episodic to persistent wheezing • 411 infants first thee years of life ICS or placebo • At 5 years of age no difference between lung function or symptoms or asthma medication use between placebo group or ICS group

  43. Intermittent Use of ICS Con Pro Budesonide 1 mg BID for 7 days at first onset of symptoms as effective as budesonide 0.5 mg qhs for 12-53 month old patients Meta-analysis no difference in daily ICS vs. intermittent in need for oral steroids but daily ICS better control and more symptoms free days • Intermittent inhaled budesonide at 400 mcg BID x 7 days less effective than daily ICS in children 5-10 years old • No difference in placebo vs. high dosed ICS for 3 days at the first signs of a viral URI with wheezing

  44. Leukotriene Receptor Agonists • Cysteinyl leukotrienes found in BAL in asthmatic patients • Inhibit production at various points in the cascade • Adjuvant therapy to ICS in patients > 1 year old • No evidence to support use as first line controller agent or as intermittent therapy • Can be used to step down therapy from ICS or in mild patient who cannot tolerate ICS

  45. Montelukast VS. Placebo Vs. ICS Meta-analysis in mild to moderate persistent asthma children ICS had better pulmonary function and better asthma control ICS more cost effective • 2-5 years olds • Intermittent asthma associated with viral symptoms • Better than placebo with a reduced rate of exacerbations and decreased use of ICS

  46. Response variability • Double cross over ( 6-17 years old) – Fluticasone and montelukast • 17 % responded to both medications • 23 % responded to fluticasone only • 5% to montelukast only • 55% to neither • Inhaled steroids as the first line controller agent • Intermittent use of moneltukast was associated with some improvement but not difference from placebo in hospitalizations, albuterol use or oral steroids use • More studies needed

  47. Long Acting Beta Agonists • Used as an adjuvant to ICS • Should not be used for acute exacerbations • Once control is obtained, effort should be made to go to a single agent ICS • Reserved for patients who “ fail” medium dose ICS • Black box warning • May increase the chance of severe asthma episodes and asthma related deaths

  48. Anti IgE ( Omalizumab) • Monoclonal anti IgE • Moderate to severe asthma • Not controlled on ICS • Elevated IgE levels • Approved if > 12 year old in US • IgE levels 30 -700 • Positive allergy testing

  49. Chronic Oral Steroids • Severe persistent asthma • Long term effects • Adrenal suppression • Weight gain • Diabetes • Hypertension • Cataracts • Delayed growth • Immune suppression • Osteoporosis • Behavioral effects • Lowest possible dose, every other day administration, trying all other modalities is preferable

More Related